The easiest category to uplist to NASDAQ would be
Post# of 152639


The best IMO would be the Capital Market, Market value. The share price needs to be above $2 for 90 days, but it needs 4M in shareholder equity. The shareholder’s equity went from -13M last may to -8M in November, I assume from the pre-inventory build-up. Once the drug is approved, I believe from looking at GILD for example, but I’m not 100% sure, this the will show up as inventory at market value, i.e, 200M, which should push the shareholder equity way above the needed requirement.



